A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
National Cancer Institute (NCI)
Trishula Therapeutics, Inc.
M.D. Anderson Cancer Center
Ohio State University Comprehensive Cancer Center
University of California, San Francisco